MedTrace Logo

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

NCT04616131 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2026-06-18

No results posted yet for this study

Summary

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Conditions

  • Pancreas Cancer

Sponsors & Collaborators

Principal Investigators

  • Akhil Chawla, MD · Northwestern Medicine Warrenville

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2027-10-01
Completion
2029-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04616131 on ClinicalTrials.gov